Disease · MONDO_0021228

brainstem neoplasm

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. brainstem neoplasm. Diseases, record MONDO_0021228. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0021228

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: brainstem neoplasm; Open Targets
Open Targets ID: MONDO_0021228; Open Targets
Other names: Brain Stem Neoplasms, Brain stem neoplasm, brain stem tumor, brain stem tumour, brainstem neoplasm (disease), brainstem tumor, brainstem tumour, neoplasm of brain stem, neoplasm of brainstem, neoplasm of the brain stem, neoplasm of the brainstem, tumor of brain stem, tumor of brainstem, tumor of the brain stem, tumor of the brainstem, tumour of brain stem, tumour of brainstem, tumour of the brain stem, tumour of the brainstem; Open Targets
NCI Thesaurus: C4869; NCI Thesaurus
Orphanet: ORPHA:36414; Orphanet
Highest stage of its drugs: Phase 2, for 9 of its 9 drugs, from ClinicalTrials.gov; Open Targets

Drugs9

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
CISPLATIN	CHEMBL11359	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
TEMOZOLOMIDE	CHEMBL810	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
6-O-BENZYLGUANINE	CHEMBL407874	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
CARBOPLATIN	CHEMBL1351	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
CYCLOPHOSPHAMIDE	CHEMBL1200796	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
IRINOTECAN	CHEMBL481	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
METHOTREXATE	CHEMBL34259	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
NIMOTUZUMAB	CHEMBL2108359	Antibody	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
VINCRISTINE	CHEMBL90555	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets

Targets18

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
DHFR	Dihydrofolate reductase	1	Dihydrofolate reductase inhibitor	Phase 2	https://conductscience.org/library/genes/1719	Drugs and targets
EGFR	Epidermal growth factor receptor	1	Epidermal growth factor receptor erbB1 inhibitor	Phase 2	https://conductscience.org/library/genes/1956	Drugs and targets
TOP1	DNA topoisomerase 1	1	DNA topoisomerase I inhibitor	Phase 2	https://conductscience.org/library/genes/7150	Drugs and targets
TUBA1A	Tubulin	1	Tubulin inhibitor	Phase 2	https://conductscience.org/library/genes/7846	Drugs and targets
TUBA1B	Tubulin	1	Tubulin inhibitor	Phase 2	https://conductscience.org/library/genes/10376	Drugs and targets
TUBA1C	Tubulin	1	Tubulin inhibitor	Phase 2	https://conductscience.org/library/genes/84790	Drugs and targets
TUBA3C	Tubulin	1	Tubulin inhibitor	Phase 2	https://conductscience.org/library/genes/7278	Drugs and targets
TUBA3E	Tubulin	1	Tubulin inhibitor	Phase 2	https://conductscience.org/library/genes/112714	Drugs and targets
TUBA4A	Tubulin	1	Tubulin inhibitor	Phase 2	https://conductscience.org/library/genes/7277	Drugs and targets
TUBB	Tubulin	1	Tubulin inhibitor	Phase 2	https://conductscience.org/library/genes/203068	Drugs and targets

1 to 10 of 18

See all 18 targets

Trials4

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT00275002	O6-Benzylguanine and Temozolomide in Treating Young Patients With Recurrent or Progressive Gliomas or Brain Stem Tumors	Phase 2	41	2011-08-09	Brain and Central Nervous System Tumors	6-O-BENZYLGUANINE, TEMOZOLOMIDE	Its record names the disease	ClinicalTrials.gov
NCT00281905	Combination Chemotherapy With or Without Radiation Therapy in Treating Children With Brain Tumors	Phase 2	50		Brain and Central Nervous System Tumors, Neuroblastoma	CARBOPLATIN, CISPLATIN, CYCLOPHOSPHAMIDE, METHOTREXATE, VINCRISTINE	Its record names the disease	ClinicalTrials.gov
NCT01574092	Irinotecan in Combination With Cisplatin in Pediatric Patients With Unfavorable Prognosis Gliomas	Phase 2	39		Pediatric High Risk Gliomas	CISPLATIN, IRINOTECAN	Its record names the disease	ClinicalTrials.gov
NCT02672241	Nimotuzumab in Combination With Radio-chemotherapy for the Treatment of Brainstem Tumor in Children	Phase 2	30		Childhood Brain Stem Neoplasm	NIMOTUZUMAB, TEMOZOLOMIDE	Its record names the disease	ClinicalTrials.gov

Comparisons in its trials2

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Recurrent High-Grade Gliomas vs Recurrent Brain Stem Tumors: Number of Patients With Grade 3 or 4 Adverse Events at Least Possibly Related to the Combination of O6-benzylguanine and Temozolomide	16 of 25	10 of 16	41	NCT00275002	Trial comparisons
Recurrent High-Grade Gliomas vs Recurrent Brain Stem Tumors: serious adverse events	15 of 25	12 of 16	41	NCT00275002	Trial comparisons

Papers from its trials0

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

None in this release.

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0021228

GET https://conductscience.org/api/diseases/v1/MONDO_0021228/drugs

API reference For AI assistants